Table IV.
Correlations between the EZH2/HDAC1/2 expression and the clinicopathological characteristics in PTCL-NOS.
| EZH2 expression | HDAC1 expression | HDAC2 expression | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Characteristic | High | Low | P-value | High | Low | P-value | High | Low | P-value |
| Sex | |||||||||
| Male | 20 (62.5) | 12 (37.5) | 0.420 | 18 (56.2) | 14 (43.8) | 0.213 | 17 (53.1) | 15 (46.9) | 0.434 |
| Female | 9 (81.8) | 2 (18.2) | 14 (73.7) | 5 (26.3) | 8 (72.7) | 3 (27.3) | |||
| Age, years | |||||||||
| ≤60 | 15 (73.7) | 9 (26.3) | 0.437 | 16 (66.7) | 8 (33.3) | 0.107 | 14 (58.3) | 10 (41.7) | 0.977 |
| >60 | 14 (62.5) | 5 (37.5) | 8 (42.1) | 11 (57.9) | 11 (57.9) | 8 (42.1) | |||
| B-symptoms | |||||||||
| Present | 20 (74.1) | 7 (25.9) | 0.228 | 17 (63.0) | 10 (37.0) | 0.220 | 16 (59.3) | 11 (40.7) | 0.847 |
| Absent | 9 (56.3) | 7 (43.7) | 7 (43.8) | 9 (56.3) | 9 (56.2) | 7 (43.8) | |||
| Marrow involvement | |||||||||
| Present | 12 (85.7) | 2 (14.3) | 0.153 | 8 (57.1) | 6 (42.9) | 0.903 | 11 (78.6) | 3 (21.4) | 0.059 |
| Absent | 17 (58.6) | 12 (41.4) | 16 (55.2) | 13 (44.8) | 14 (48.3) | 15 (51.7) | |||
| Splenomegaly | |||||||||
| Present | 11 (55.0) | 9 (45.0) | 0.104 | 10 (50.0) | 10 (50.0) | 0.474 | 9 (45.0) | 11 (55.0) | 0.103 |
| Absent | 18 (78.3) | 5 (21.7) | 14 (60.9) | 9 (39.1) | 16 (69.6) | 7 (30.4) | |||
| Stage | |||||||||
| I–II | 5 (38.5) | 8 (61.5) | 0.021b | 4 (30.8) | 9 (69.2) | 0.029b | 2 (47.4) | 11 (52.6) | 0.000a |
| III–IV | 24 (80.0) | 6 (20.0) | 20 (66.7) | 10 (33.3) | 23 (80.9) | 7 (19.1) | |||
| IPI | |||||||||
| 0–2 | 14 (60.9) | 9 (39.1) | 0.324 | 10 (43.5) | 13 (56.5) | 0.081 | 11 (47.8) | 12 (52.2) | 0.142 |
| 3–5 | 15 (75.0) | 5 (25.0) | 14 (70.0) | 6 (30.0) | 4 (70.0) | 6 (30.0) | |||
| B2M | |||||||||
| >Upper limit of normal | 18 (75.0) | 6 (25.0) | 0.235 | 18 (75.0) | 6 (25.0) | 0.004a | 15 (62.5) | 9 (37.5) | 0.515 |
| Normal | 11 (57.9) | 8 (42.1) | 6 (31.6) | 13 (68.4) | 10 (52.6) | 9 (47.4) | |||
| LDH | |||||||||
| >Upper limit of normal | 20 (76.9) | 6 (23.1) | 0.101 | 18 (69.2) | 8 (30.8) | 0.028 | 16 (61.5) | 10 (38.5) | 0.576 |
| Normal | 9 (52.9) | 8 (47.1) | 6 (35.3) | 11 (64.7) | 9 (52.9) | 8 (47.1) | |||
| WBC | |||||||||
| >Upper limit of normal | 7 (50.0) | 7 (50.0) | 0.177 | 7 (50.0) | 7 (50.0) | 0.594 | 8 (57.1) | 6 (42.9) | 0.927 |
| Normal | 22 (78.6) | 7 (21.4) | 17 (58.6) | 12 (41.4) | 17 (58.6) | 12 (41.4) | |||
| Ki-67 | |||||||||
| ≥30% | 21 (80.8) | 5 (19.2) | 0.021b | 15 (57.7) | 11 (42.3) | 0.759 | 17 (65.4) | 9 (34.6) | 0.234 |
| <30% | 8 (47.1) | 9 (52.9) | 9 (52.9) | 8 (47.1) | 8 (47.1) | 9 (52.9) | |||
a
P<0.01
b
P<0.05. EZH2, enhancer of zeste homolog 2; HDAC, histone deacetylase; PTCL-NOS, PTCL not otherwise specified; IPI, international prognostic index; B2M, β2 microglobulin; LDH, lactate dehydrogenase; WBC, white blood count.